A Single-arm, Open-label, Multi-center, Phase I Expansion Study Evaluating the Efficacy and Safety of HM95573 Monotherapy in Patients With BRAF, KRAS or NRAS Mutation-positive Solid Cancers
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Belvarafenib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 06 Aug 2020 Status changed from recruiting to completed.
- 06 Apr 2020 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Sep 2017).
- 04 Jun 2019 Results of overall safety and efficacy findings from 2 phase I studies NCT02405065, NCT03118817 presented at the 55th Annual Meeting of the American Society of Clinical Oncology